Hydroxychloroquinesulfaat Teva

Hydroxychloroquine sulfate, the active ingredient in Hydroxychloroquinesulfaat Teva, is an antimalarial presented as an oral dosage form for systemic use. It is employed in the prevention and treatment of malaria and in managing autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosus.

GNH USA supplies Hydroxychloroquinesulfaat Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Hydroxychloroquine sulfate is used in diseases where it modulates immune activity or treats parasitic infection. - Malaria prophylaxis and treatment: Prevents infection and treats acute episodes of Plasmodium malaria in adults and children. - Rheumatoid arthritis: Reduces joint inflammation and slows disease progression in patients with active disease. - Systemic lupus erythematosus: Controls disease activity and decreases flare frequency in affected individuals.

Hydroxychloroquine sulfate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting - Diarrhea - Abdominal discomfort - Headache - Skin rash or itching - Visual disturbances such as blurred vision

Serious or Rare Side Effects: - Retinal toxicity leading to vision loss - Cardiac arrhythmias including QT prolongation - Severe hypoglycemia - Hemolytic anemia in G6PD‑deficient patients - Severe cutaneous adverse reactions (e.g., Stevens‑Johnson syndrome)

Hydroxychloroquine requires careful monitoring in several clinical situations. - Pregnancy: Use only if potential benefit justifies potential risk; safety data are limited. - Renal impairment: Adjust dosing and monitor plasma levels in patients with reduced kidney function. - Hepatic impairment: Use cautiously; monitor liver function tests. - G6PD deficiency: Assess risk of hemolysis before initiating therapy. - Ophthalmologic monitoring: Perform baseline and periodic eye examinations to detect retinal changes. - Store at ambient temperature: Keep below 25 °C, in the original container, protected from moisture and light.

Hydroxychloroquine can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Concomitant use with other QT‑prolonging agents (e.g., quinidine, macrolide antibiotics) may increase risk of cardiac arrhythmia. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine) can markedly reduce hydroxychloroquine plasma concentrations. - Antacids containing aluminum or magnesium may decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Digoxin: Hydroxychloroquine may increase serum digoxin levels; monitor for toxicity. - Insulin or oral hypoglycemics: May potentiate hypoglycemic effect; check blood glucose regularly. - Cyclosporine: Potential for increased nephrotoxicity; monitor renal function. - Warfarin: May enhance anticoagulant effect; monitor INR.